Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients

Chest

Volumn 127, Issue 4, 2005, Pages 1276-1282

  Kadowaki, Maiko ^a   Demura, Yoshiki ^a   Mizuno, Shiro ^a   Uesaka, Daisuke ^a   Ameshima, Shingo ^a   Miyamori, Isamu ^a   Ishizaki, Takeshi ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Ampicillin sulbactam; Aspiration pneumonia; Clindamycin; Medical cost; Methicillin resistant Staphylococcus aureus; Panipenem betamiprom; Prospective clinical study

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM; BETA LACTAMASE INHIBITOR; BETAMIPROM PLUS PANIPENEM; CARBAPENEM; CLINDAMYCIN; SULTAMICILLIN; UNCLASSIFIED DRUG; AMPICILLIN; ANTIINFECTIVE AGENT; BETA ALANINE; DRUG DERIVATIVE; PANIPENEM PLUS BETAMIPRON; PANIPENEM-BETAMIPRON; SULBACTAM; THIENAMYCIN DERIVATIVE;

AGED; AGING; ARTICLE; ASPIRATION PNEUMONIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; COMPARATIVE STUDY; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; AMPICILLIN; ANTI-BACTERIAL AGENTS; BETA-ALANINE; CLINDAMYCIN; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PNEUMONIA, ASPIRATION; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SULBACTAM; THIENAMYCINS;

EID: 19044382632     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.4.1276     Document Type: Article

References (25)

1. Kikuchi R, Watanabe N, Konno T, et al. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med 1994; 150:251-253
2. Bartlett JG, Gorbach SL, Finegold SM. The bacteriology of aspiration pneumonia. Am J Med 1974; 56:202-207
3. Sydney MF. Aspiration pneumonia. Rev Infect Dis 1991; 13(suppl):S737-S742
4. The Committee of the Japanese Respiratory Society. Guidelines for management of hospital-acquired pneumonia: the basic concept of management for hospital-acquired pneumonia in adults [in Japanese]. Tokyo, Japan: Kyorinsya, 2002; 27-34
5. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. Am J Respir Crit Care Med 1995; 153:1711-1725
6. The Infectious Diseases of America. Practice guidelines of the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31:347-382
7. Marik P. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001; 344:665-671
8. Marik P, Kaplan D. Aspiration pneumonia and dysphagia in the elderly. Chest 2003; 124:328-336
9. Saito A, Miki F, Oizumi K, et al. Clinical evaluation methods for new antimicrobial agents to treat respiratory infections: report of the Committee for the Respiratory System, Japan Society of Chemotherapy. J Infect Chemother 1999; 5:110-123
10. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am J Respir Crit Care Med 1993; 148:1418-1426
11. Janssens J-P, Krause K-H. Pneumonia in the very old. Lancet Infect Dis 2004; 4:112-124
12. Theerthakarai R, El-Halees W, Ismail M, et al. Nonvalue of the initial microbiological studies in the management of nonsevere community-acquired pneumonia. Chest 2001; 119: 181-184
13. Garner JS. Guidelines for isolation precautions in hospitals. Infect Control Hosp Epidemiol 1996; 17:53-80
14. Joseph P, Lynch III. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 2001; 119:373S-384S
15. Malin HK, Victoria JF. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134:298-314
16. de Lencastre H, de Jonge BL, Matthews PR, et al. Molecular aspects of methicillin resistance in Staphylococcus aureus. J Antimicrob Chemother 1994; 33:7-24
17. Ghuysen JM. 1991. Serine β-lactamases and penicillin binding proteins. Annu Rev Microbiol 1991; 45:37-67
18. Laurel SA, Virginia DS, Angela MN, et al. Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus. Diag Microbiol Infect Dis 2002; 43:225-232
19. David MS, Dale NG, Joseph FJ, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25:584-599
20. Shimada J, Kawahara Y. Overview of a new carbapenem, panipenem/ betamipron. Drugs Exp Clin Res 1994; 20:241-245
21. Goa KL, Noble S. Panipenem/betamipron. Drugs 2003; 63:913-925
22. Shibuya T, Kitamura S, Tani G, et al. Evaluation of panipenem/betamipron (PAPM/BP) in pneumonia in elderly patients. J Infect Chemother 2002; 8:151-154
23. Read RC. Evidence-based medicine: empiric antibiotic therapy in community-acquired pneumonia. J Infect 1999; 39: 171-178
24. Fine MJ, Able TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-250
25. Nishimura O, Taniguchi H, Kondoh T, et al. The utility of the pneumonia PORT prediction rule for evaluating the severity of community-acquired pneumonia in Japan: the relationship between disease severity and drug-resistant Streptococccus pneumoniae. Kansenshogaku Zasshi 2002; 76:1003-1009